Improve Research Reproducibility A Bio-protocol resource
- Home
- Protocols
-
Ask a
question
Favorite
Dexamethasone (Fresenius Kabi USA) was injected IV (4 mg/kg) at 2 pm on day –1 and then at 7:30 am and 2:30 pm on day 0. Anakinra (Kineret, Swedish Orphan Biovitrum, Stockholm, Sweden) was administered subcutaneously at a 50-mg flat dose, 2 doses each on days –1 and 0 (1 hour before and 6 hours after HDAd injection). Tocilizumab (Actemra, Genentech Inc., South San Francisco, CA) was injected IV at 8 mg/kg, 2 doses each on days –1 and 0 (1 hour before and 6 hours after HDAd injection) via diluted infusions (50 mL each).
Copyright and License information: ©2022 The American Society of Hematology.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Post a Question0 Q&A
